{"title":"狂犬病毒糖蛋白新保守b细胞表位的鉴定。","authors":"Yumei Chen, Xiaohui Zhang, Yanhua Qi, Hongliang Liu, Enping Liu, Xifang Zhu, Jingming Zhou, Chao Liang, Sixuan Wu, Aiping Wang","doi":"10.1007/s00430-026-00887-x","DOIUrl":null,"url":null,"abstract":"<p><p>Rabies virus (RABV), a single-stranded RNA virus, invades the central nervous system and causes acute, zoonotic diseases worldwide. The glycoprotein (G) of RABV is the only surface antigen responsible for inducing potent neutralizing antibodies, making it a key target for medical countermeasures. In this study, two anti-G protein monoclonal antibodies (mAbs) were prepared using hybridoma cell technology, with their high specificity and robust reactivity validated by indirect enzyme-linked immunosorbent assay (i-ELISA), indirect immunofluorescence assay (IFA) and Western blot. Through systematic epitope mapping using a series of truncated G protein fragments, two mAbs (1G2 and 4E5) were found to recognize a minimal linear epitope, AEDFVEVHLP (amino acids 412-421) through Dot-ELISA and i-ELISA. Alanine-scanning mutagenesis further defined the core binding residues within this epitope as <sup>412</sup>Ala-Glu-Asp-Phe-Val<sup>416</sup>, <sup>418</sup>Val, <sup>420</sup>Leu, and <sup>421</sup>Pro. Bioinformatic analysis with MEGA software revealed highly conserved with conservative substitutions of this epitope across diverse RABV of genotype 1. Homology modeling with SWISS-MODEL localized the epitope \"<sup>412</sup>AEDFVEVHLP<sup>421</sup>\" to a solvent-exposed α-helical conformation on the G protein surface. And this epitope is located in the extracellular C-terminal region, Prior studies have demonstrated that this region plays a role in stabilizing the trimerization of the rabies virus glycoprotein (RVG). In conclusion, our study identifies a novel, highly conserved with conservative substitutions linear B-cell epitope on the RABV glycoprotein, providing a precise molecular target for the rational design of next-generation epitope-based vaccines and specific diagnostic tools.</p>","PeriodicalId":18369,"journal":{"name":"Medical Microbiology and Immunology","volume":"215 1","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Identification of a novel conserved B-cell epitope in the glycoprotein of rabies virus.\",\"authors\":\"Yumei Chen, Xiaohui Zhang, Yanhua Qi, Hongliang Liu, Enping Liu, Xifang Zhu, Jingming Zhou, Chao Liang, Sixuan Wu, Aiping Wang\",\"doi\":\"10.1007/s00430-026-00887-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Rabies virus (RABV), a single-stranded RNA virus, invades the central nervous system and causes acute, zoonotic diseases worldwide. The glycoprotein (G) of RABV is the only surface antigen responsible for inducing potent neutralizing antibodies, making it a key target for medical countermeasures. In this study, two anti-G protein monoclonal antibodies (mAbs) were prepared using hybridoma cell technology, with their high specificity and robust reactivity validated by indirect enzyme-linked immunosorbent assay (i-ELISA), indirect immunofluorescence assay (IFA) and Western blot. Through systematic epitope mapping using a series of truncated G protein fragments, two mAbs (1G2 and 4E5) were found to recognize a minimal linear epitope, AEDFVEVHLP (amino acids 412-421) through Dot-ELISA and i-ELISA. Alanine-scanning mutagenesis further defined the core binding residues within this epitope as <sup>412</sup>Ala-Glu-Asp-Phe-Val<sup>416</sup>, <sup>418</sup>Val, <sup>420</sup>Leu, and <sup>421</sup>Pro. Bioinformatic analysis with MEGA software revealed highly conserved with conservative substitutions of this epitope across diverse RABV of genotype 1. Homology modeling with SWISS-MODEL localized the epitope \\\"<sup>412</sup>AEDFVEVHLP<sup>421</sup>\\\" to a solvent-exposed α-helical conformation on the G protein surface. And this epitope is located in the extracellular C-terminal region, Prior studies have demonstrated that this region plays a role in stabilizing the trimerization of the rabies virus glycoprotein (RVG). In conclusion, our study identifies a novel, highly conserved with conservative substitutions linear B-cell epitope on the RABV glycoprotein, providing a precise molecular target for the rational design of next-generation epitope-based vaccines and specific diagnostic tools.</p>\",\"PeriodicalId\":18369,\"journal\":{\"name\":\"Medical Microbiology and Immunology\",\"volume\":\"215 1\",\"pages\":\"\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2026-09-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Microbiology and Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00430-026-00887-x\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Microbiology and Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00430-026-00887-x","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
狂犬病毒(RABV)是一种单链RNA病毒,侵入中枢神经系统并在世界范围内引起急性人畜共患疾病。RABV的糖蛋白(G)是唯一负责诱导强效中和抗体的表面抗原,使其成为医学对策的关键靶点。本研究利用杂杂瘤细胞技术制备了两种抗g蛋白单克隆抗体(mAbs),通过间接酶联免疫吸附试验(i-ELISA)、间接免疫荧光试验(IFA)和Western blot验证了其高特异性和强反应性。通过一系列截断的G蛋白片段进行系统的表位定位,通过Dot-ELISA和i-ELISA发现两个单抗(1G2和4E5)识别最小线性表位AEDFVEVHLP(氨基酸412-421)。丙氨酸扫描诱变进一步确定该表位内的核心结合残基为412ala - glu - asp - ph - val416、418Val、420Leu和421Pro。生物信息学分析显示,该表位在不同的RABV基因型1中具有高度保守性和保守性。通过SWISS-MODEL进行同源性建模,将表位“412AEDFVEVHLP421”定位为G蛋白表面溶剂暴露的α-螺旋构象。该表位位于细胞外c端区,前期研究表明该区域在稳定狂犬病毒糖蛋白(RVG)的三聚体化中起作用。总之,我们的研究确定了RABV糖蛋白上一个高度保守的线性b细胞表位,为合理设计下一代表位疫苗和特异性诊断工具提供了一个精确的分子靶标。
Identification of a novel conserved B-cell epitope in the glycoprotein of rabies virus.
Rabies virus (RABV), a single-stranded RNA virus, invades the central nervous system and causes acute, zoonotic diseases worldwide. The glycoprotein (G) of RABV is the only surface antigen responsible for inducing potent neutralizing antibodies, making it a key target for medical countermeasures. In this study, two anti-G protein monoclonal antibodies (mAbs) were prepared using hybridoma cell technology, with their high specificity and robust reactivity validated by indirect enzyme-linked immunosorbent assay (i-ELISA), indirect immunofluorescence assay (IFA) and Western blot. Through systematic epitope mapping using a series of truncated G protein fragments, two mAbs (1G2 and 4E5) were found to recognize a minimal linear epitope, AEDFVEVHLP (amino acids 412-421) through Dot-ELISA and i-ELISA. Alanine-scanning mutagenesis further defined the core binding residues within this epitope as 412Ala-Glu-Asp-Phe-Val416, 418Val, 420Leu, and 421Pro. Bioinformatic analysis with MEGA software revealed highly conserved with conservative substitutions of this epitope across diverse RABV of genotype 1. Homology modeling with SWISS-MODEL localized the epitope "412AEDFVEVHLP421" to a solvent-exposed α-helical conformation on the G protein surface. And this epitope is located in the extracellular C-terminal region, Prior studies have demonstrated that this region plays a role in stabilizing the trimerization of the rabies virus glycoprotein (RVG). In conclusion, our study identifies a novel, highly conserved with conservative substitutions linear B-cell epitope on the RABV glycoprotein, providing a precise molecular target for the rational design of next-generation epitope-based vaccines and specific diagnostic tools.
期刊介绍:
Medical Microbiology and Immunology (MMIM) publishes key findings on all aspects of the interrelationship between infectious agents and the immune system of their hosts. The journal´s main focus is original research work on intrinsic, innate or adaptive immune responses to viral, bacterial, fungal and parasitic (protozoan and helminthic) infections and on the virulence of the respective infectious pathogens.
MMIM covers basic, translational as well as clinical research in infectious diseases and infectious disease immunology. Basic research using cell cultures, organoid, and animal models are welcome, provided that the models have a clinical correlate and address a relevant medical question.
The journal also considers manuscripts on the epidemiology of infectious diseases, including the emergence and epidemic spreading of pathogens and the development of resistance to anti-infective therapies, and on novel vaccines and other innovative measurements of prevention.
The following categories of manuscripts will not be considered for publication in MMIM:
submissions of preliminary work, of merely descriptive data sets without investigation of mechanisms or of limited global interest,
manuscripts on existing or novel anti-infective compounds, which focus on pharmaceutical or pharmacological aspects of the drugs,
manuscripts on existing or modified vaccines, unless they report on experimental or clinical efficacy studies or provide new immunological information on their mode of action,
manuscripts on the diagnostics of infectious diseases, unless they offer a novel concept to solve a pending diagnostic problem,
case reports or case series, unless they are embedded in a study that focuses on the anti-infectious immune response and/or on the virulence of a pathogen.